Metabolic Syndrome and Risk of Pancreatic Cancer: a Population-based Prospective Cohort Study
A partir de données de l'"UK Biobank" portant sur 474 929 individus non atteints d'un cancer (durée médiane de suivi : 6,6 ans), cette étude analyse l'association entre des composantes du syndrome métabolique et le risque de cancer du pancréas (565 cas)
Metabolic syndrome (MetS) and its components may link to pancreatic cancer risk, however, current epidemiological evidence is limited, and the potential mechanisms underlying the associations remain unclear. To investigate this, we carried out the prospective cohort study of 474 929 participants without a diagnosis of cancer based on UK Biobank dataset. MetS was defined according to the International Diabetes Federation criteria and pancreatic cancer was identified through linkage to U.K. cancer registries (median follow-up time: 6.6 years). We evaluated hazard ratio (HR) and 95% confidence interval (CI) with Cox proportional hazards regression, adjusting for demography and lifestyle factors. Restricted cubic spline was performed for each MetS component to investigate their possible non-linear associations with risk of pancreatic cancer. During 3 112 566 person-years of follow-up, 565 cases of pancreatic cancer were identified. Individuals with MetS (HR = 1.31, 95% CI, 1.09-1.56), central obesity (HR = 1.24, 95% CI, 1.02-1.50) and hyperglycaemia (HR = 1.60, 95% CI, 1.31-1.97) had increased risk of pancreatic cancer. Higher waist circumference and blood glucose were independently associated with pancreatic cancer, with no evidence against non-linearity. Although elevated CRP (≥ 1.00 mg/dL) showed a positive association with the risk for pancreatic cancer, the effect was substantially increased only in participants with MetS and CRP ≥1.00 mg/dL. This study demonstrated a positive association between MetS and increased risk of pancreatic cancer, with two of the MetS components, waist circumference and blood glucose, showing independent associations in linear manner. Our study also suggested a potential joint effect of MetS and CRP in pancreas tumorigenesis. This article is protected by copyright. All rights reserved.